Last reviewed · How we verify
Rubramin Pc (CYANOCOBALAMIN)
At a glance
| Generic name | CYANOCOBALAMIN |
|---|---|
| Sponsor | Bristol Myers Squibb |
| Drug class | Vitamin C [EPC] |
| Target | Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1949 |
Approved indications
- Cobalamin deficiency
- Iron deficiency anemia
- Megaloblastic anemia due to folate deficiency
- Pernicious anemia
- Prevention of Vitamin B12 Deficiency
- Vitamin Deficiency Prevention
- Vitamin deficiency
Boxed warnings
- WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
Common side effects
- Pulmonary edema
- Congestive heart failure
- Peripheral vascular thrombosis
- Anaphylactic shock
- Death
- Polycythemia vera
- Mild transient diarrhea
- Itching
- Transitory exanthema
- Feeling of swelling of entire body
Drug interactions
- esomeprazole
- lansoprazole
- omeprazole
- pantoprazole
- rabeprazole
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Clinical and Laboratory Study of Methylmalonic Acidemia
- Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older
- Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment (NA)
- Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters
- Vegan Diet and Immune-Inflammatory Outcomes in Asthma and Healthy Adults (NA)
- Microbiome and Health Indicators in People With Obesity, Prediabetes and Type 2 Diabetes Undergoing a Lifestyle Intervention (NA)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rubramin Pc CI brief — competitive landscape report
- Rubramin Pc updates RSS · CI watch RSS